Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

307.71 +20.19 (+7.02%)
Streaming Delayed Price Updated: 2:39 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug
Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August. 
Via Benzinga
5 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Via The Motley Fool
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment,... 
Via Stocktwits
Topics Death
Earnings Scheduled For May 1, 2025
Via Benzinga
Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview
Via Benzinga
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Via The Motley Fool
Earnings Scheduled For February 26, 2025
Via Benzinga
Why Madrigal Pharmaceuticals Stock Is Sinking Today
Via The Motley Fool
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations. 
Via Benzinga
Earnings Preview For Madrigal Pharmaceuticals
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
Via The Motley Fool
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. 
Via MarketBeat
Top 3 Health Care Stocks That May Dip This Month
Via Benzinga
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
Via The Motley Fool
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
Via The Motley Fool
MDGL: A Promising Play In The Weight Loss Drug Space
The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now... 
Via Talk Markets
Topics Stocks / Equities
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
There's a bright future ahead for this company. 
Via The Motley Fool
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
Via Benzinga
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Is Madrigal Pharmaceuticals Stock a Buy?
The biotech could be worth a lot more in 10 years. 
Via The Motley Fool
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
One player's minor pain is another's moderate gain. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations. 
Via Investor's Business Daily
Topics Earnings
Is It Too Late to Buy Madrigal Pharmaceuticals Stock?
Will being the first to its market ensure that its future is bright? 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.